Logo image
The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus
Journal article   Open access   Peer reviewed

The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus

Takanori Furukawa, Norman van Rhijn, Marcin Fraczek, Fabio Gsaller, Emma Davies, Paul Carr, Sara Gago, Rachael Fortune-Grant, Sayema Rahman, Jane Mabey Gilsenan, …
Nature communications, Vol.11(1), pp.427-427
01/22/2020
DOI: 10.1038/s41467-019-14191-1
PMCID: PMC7194077
PMID: 31969561
url
https://doi.org/10.1038/s41467-019-14191-1View
Published (Version of record) Open Access

Abstract

The frequency of antifungal resistance, particularly to the azole class of ergosterol biosynthetic inhibitors, is a growing global health problem. Survival rates for those infected with resistant isolates are exceptionally low. Beyond modification of the drug target, our understanding of the molecular basis of azole resistance in the fungal pathogen Aspergillus fumigatus is limited. We reasoned that clinically relevant antifungal resistance could derive from transcriptional rewiring, promoting drug resistance without concomitant reductions in pathogenicity. Here we report a genome-wide annotation of transcriptional regulators in A. fumigatus and construction of a library of 484 transcription factor null mutants. We identify 12 regulators that have a demonstrable role in itraconazole susceptibility and show that loss of the negative cofactor 2 complex leads to resistance, not only to the azoles but also the salvage therapeutics amphotericin B and terbinafine without significantly affecting pathogenicity.
Amphotericin B - pharmacology Antifungal Agents - pharmacology Aspergillus fumigatus - drug effects Aspergillus fumigatus - genetics Aspergillus fumigatus - metabolism Azoles - pharmacology Drug Resistance, Fungal Fungal Proteins - genetics Fungal Proteins - metabolism Microbial Sensitivity Tests

Details

Logo image